Ionis Price Targets Cut After Trial Miss, September 8 2026

Three healthcare names drew eight analyst actions on Tuesday, the first session after the Labor Day break. Ionis took five of them, Amgen two and BioNTech one. One desk downgraded twice. Six target figures came down and not one was raised.

Ionis Books $268 Million In Quarterly Revenue And Draws Five Analyst Actions

Ionis makes RNA-targeted medicines. Each one is a short strand built to switch off a single gene. Four product lines carry the revenue. Two are its own, TRYNGOLZA and DAWNZERA. The other two are royalties on SPINRAZA and WAINUA, which partners sell. Revenue over the last twelve months was $874 million.

What The Pelacarsen Trial Showed

Novartis released topline Phase 3 results for pelacarsen on 4 September. Ionis discovered the drug and licensed it to Novartis. The Lp(a)HORIZON trial enrolled 8,323 patients with elevated lipoprotein(a) and established cardiovascular disease.

Lipoprotein(a) is a fatty particle in the blood linked to heart disease. Pelacarsen is built to lower it. The primary endpoint combined four kinds of event. They were cardiovascular death, non-fatal heart attack, non-fatal stroke, and urgent coronary revascularisation needing a hospital stay. That endpoint was not met. The drug did lower lipoprotein(a) against placebo. Shreeram Aradhye, the Novartis president of development and chief medical officer, said the findings did not demonstrate that this translated into reduced cardiovascular risk in the overall group. The 4 September release said the data will go to a medical congress.

The FDA approved ZANVASTRO, the Ionis drug zilganersen, on 3 September. It is the first disease-modifying treatment for Alexander disease.

Ionis’s Finances Going In

Ionis reported its second quarter on 29 July. Revenue was $268 million, against $452 million a year earlier. The net loss was $115 million, or $0.69 a share. Cash and short-term investments stood at $2.055 billion on 30 June.

Ionis’s Stock Price Target News Today

Five desks acted on Tuesday and none changed a rating. Mitchell Kapoor of HC Wainwright lowered his target from $115 to $100 and stayed at Buy. Salveen Richter of Goldman Sachs cut hers from $69 to $56 at Neutral. Gary Nachman of Canaccord Genuity reduced his from $95 to $85, also at Buy. David Lebowitz of BMO Capital trimmed his from $61 to $54 at Market Perform. Michael Ulz of Morgan Stanley marked his down from $110 to $104 at Overweight.

Ionis’s Analyst Coverage

Kapoor has met 40.44 percent of his price targets, across 726 targets and ratings on 34 stocks. His targets take 91 days on average to be reached. AnaChart records 20 analysts on Ionis over the last twelve months, at an average target of $98.38.

Amgen Books $10.1 Billion In Quarterly Revenue And Draws Two Analyst Actions

Amgen makes biologic medicines. Its biggest sellers treat cholesterol, thin bones, asthma and inflamed joints. It also sells copies of rival biologics. Revenue over the last twelve months was $38.10 billion.

What Amgen’s Second Quarter Showed

Amgen reported its second quarter on 4 August. Total revenue was $10.1 billion, 10 percent above the same quarter a year earlier, and product sales were $9.537 billion. Non-GAAP earnings were $6.29 a share, 4 percent higher. On a GAAP basis earnings were $4.37 a share, against $2.65.

Repatha sales were $953 million, 37 percent higher. Evenity was $714 million, 38 percent higher. Tezspire was $486 million, 42 percent higher. Free cash flow was $3.5 billion in the quarter, against $1.9 billion a year earlier. Amgen guides to full year revenue of $38.2 billion to $39.4 billion and non-GAAP earnings of $22.30 to $23.50 a share.

Amgen’s Stock Price Target News Today

Two desks acted on Tuesday and neither moved a number. Evan Seigerman of BMO Capital downgraded Amgen to Market Perform from Outperform, holding his $450 target. He wrote that commercial execution is now priced in. Patents running out across the portfolio were part of his case. He also questioned how the obesity candidate MariTide compares with treatments already sold. Carter Gould of Cantor Fitzgerald reiterated Neutral and kept $400.

Amgen’s Analyst Coverage

Gould has met 78.96 percent of his price targets, across 659 targets and ratings on 32 stocks. His targets take 297 days on average to be reached. AnaChart records 21 analysts on Amgen over the last twelve months, at an average target of $370.32.

BioNTech Guidance Cut Of 400 Million Euros Precedes One Analyst Action

BioNTech developed the Comirnaty covid vaccine with Pfizer. That partnership is where its sales have come from. Its pipeline now runs on cancer drugs, led by pumitamig. The company sits in Mainz and reports in euros. Revenue over the last twelve months was $3.03 billion in dollar terms.

What BioNTech’s Second Quarter Showed

BioNTech reported its second quarter on 4 August. Revenue was 105.6 million euros, against 260.8 million a year earlier. The net loss was 820.8 million euros, or 3.24 euros a share. Adjusted research and development spending was 477.1 million euros, down from 509.1 million. Cash and security investments were 16.6 billion euros on 30 June.

The company cut its full year revenue guidance to a range of 1.6 billion to 1.9 billion euros, from 2.0 billion to 2.3 billion. It attributed that to softer global covid vaccine demand. On its lead cancer candidate, pumitamig, it said the drug showed encouraging efficacy in first line non-small cell lung cancer. The company added that response rates were high whatever the level of PD-L1, the protein used to sort which lung tumours respond to immunotherapy.

BioNTech’s Stock Price Target News Today

One desk acted on Tuesday. Seigerman downgraded BioNTech to Market Perform from Outperform and took his target from $128 to $105. Comirnaty is eroding more quickly than he had expected, he wrote. He also pointed to the wait for pumitamig data until 2028. A third reason was iNeST, the programme building a cancer vaccine made for each patient, where he now expects less. On pumitamig he wrote that it “looks good, but ‘good’ isn’t differentiated in a crowding field”. He pointed to rival programmes at Pfizer and at AbbVie with RemeGen.

BioNTech’s Analyst Coverage

Seigerman has met 73.28 percent of his price targets, across 882 targets and ratings on 37 stocks. His targets take 284 days on average to be reached. AnaChart records 13 analysts on BioNTech over the last twelve months, at an average target of $130.48.

Questions Readers Ask About These Numbers

Did one desk touch all three names? BMO Capital did, through two analysts in the same session.

How long does an Ionis price target take to be reached? AnaChart’s record puts the average at 495.08 days. On Amgen the average is 542.2 days, and on BioNTech 43.04 days.

The previous session’s actions are in the 4 September update. The analyst price target dataset holds the underlying record for these analysts and tickers.